Sogroya (somapacitan) Prescription HGH Treatments FDA-Approved

Reading Time: 2 minutes [451 words]

Play

Stop

Video Link: https://vimeo.com/486678523

Video Download: Sogroya Somapacitan Prescription Hgh Treatments Fda Approved

Video Stream: Sogroya Somapacitan Prescription Hgh Treatments Fda Approved

HGH Therapy has been successfully prescribed for decades to help children and adults overcome the effects of Human Growth Hormone Deficiency. One of the biggest problems with Bio-Identical Growth Hormone Treatment is that it has always required the inconvenience of daily injections.

While HGH Pens have made these injections less painful and easier to cope with, long-acting Growth Hormone formulations have always been a goal. In August, that goal was finally achieved. Sogroya HGH Therapy has recently completed FDA-Approval in the United States.

Sogroya Weekly HGH Injections by Novo Nordisk

Sogroya is a prescription Growth Hormone Treatment patented by Novo Nordisk for the treatment of adult-onset HGH Deficiency. The generic name for this drug is somapacitan.

Because Growth Hormone has historically required daily shots, patients sometimes have issues maintaining compliance due to the dosing frequency. These issues diminish the long-term effectiveness of treatment as measured by baseline IGF-1 Levels.

Sogroya is designed for weekly injection, which vastly increases ease of compliance while still providing expected results. While other companies are working out their own formulations for extended-release HGH, Novo Nordisk was the first to get an approved treatment out on the market.

Daily shots of Growth Hormone not only lead to non-compliance; they also increase the risk of some problematic side-effects associated with frequent injection, including itching and lipohypertrophy.

Clinical Trial Showcases the Effectiveness of Sogroya HGH

FDA Approval for Sagroya was achieved via successful Phase III Clinical trial. 300 patients participated in the trial. The participants were split up into three sets, all of which had been diagnosed with Hypopituitarism. One group received a placebo injection. The second group was treated with traditional daily Somatropin Injections, and the third was offered Sogroya.

Placebo patients experienced increased midsection body fat. For those taking weekly HGH Shots, Sogroya effectively treated Growth Hormone Deficiency as made evident by a reduction in abdominal fat in comparison to placebo.

Who Shouldn't Use Sogroya?

While Sogroya HGH is comparably safe as compared to Daily HGH Injections, it does carry the risk of certain side-effects, including nausea, dizziness, insomnia, and indigestion. It should not be used by patients with a history of papilledema or diabetic retinopathy. Sogroya should also never be used for childhood and adolescent Growth Hormone Deficiency. It is intended only for adults.

Who Can Benefit from Sogroya?

Sogroya provides a great opportunity for adult HGH Deficiency patients to adopt a simpler therapeutic regimen without sacrificing effectiveness. Adult-Onset Hypopituitarism is a relatively under-diagnosed medical issue. If you've experienced a combination of symptoms associated with Low HGH Levels, you may be a candidate for Sogroya Injections.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *

Your State *

Select Age (30+ only) *

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.
Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.